Mind, Mood and Microbes: Harnessing the Power of Probiotics By Clara Rodríguez Fernández 1 minutemin December 2, 2016 -Updated: onJune 22, 2022 1 minutemin Share WhatsApp Twitter Linkedin Email Newsletter Signup - Under Article / In Page"*" indicates required fieldsCompanyThis field is for validation purposes and should be left unchanged.Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*Company name*Job title*Business email* The canals of Amsterdam have attracted us this week to the capital of the Netherlands, where Winclove Probiotics has been working for more than 20 years in targeting the human microbiome. This field is now resurging, with research pointing to a close link between gut bacteria and human health. City: Amsterdam, the NetherlandsFounded: 1991Employees: 50+Financial data: €2M turnover in 2014, participant in two EU 2020 Horizon projects totaling €12MPieter Pekelharing, CEOMission: Winclove Probiotics produces probiotic food supplements to treat inflammatory bowel disease, eczema, allergy, constipation, diarrhea, vaginal infections, and even depression. Such a wide range of applications stem from the close link between the microorganisms living in our gut and human health.Comment: the company took part this week in Mind, Mood & Microbes, the first international conference on microbiota-gut-brain axis. This novel field is starting to yield innovative clinical applications that target the human microbiome, including immuno-oncology.Featured image: Labiotech mapImmunology & inflammation R&D trends and breakthrough innovations Inpart’s new report provides scientific decision-makers with a roadmap of high-impact I&I opportunities, emerging technologies, and potential future partners. Download now Explore other topics: AllergyInflammatory diseaseMicrobiomeNetherlandsPsychiatric disorders ADVERTISEMENT